Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

Stopped early · Not applicable

Conditions studied: Sleep Disorder; Breathing-Related, Heart Failure

In brief

This is a prospective, single-arm, unblinded pilot study and registry that aims to demonstrate adherence to adaptive servo-ventilation (ASV) therapy in patients with moderate to severe sleep disordered breathing who have been recently hospitalized. ASV therapy has been linked to improved outcomes in this population, but adherence to therapy is low. The AirCurve 10 ASV device that will be used for this study employs newer technologies, such as web-based monitoring and provides patients feedback, which may increase therapy adherence and therefore improve patient outcomes.

Key facts

Study ID

NCT04133350

Run by

Thomas Jefferson University

People needed

2

Starts

2019-10-16

Expected to finish

2021-02-01

Last updated by the study team

2021-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Patients 18 years or older 2. Patients with heart failure with preserved ejection fraction (HFpEF; LVEF ≥50%) 3. Hospital admission or equivalent (such as ER visit alone or clinic visit alone) and acute decompensated HF as determined by:
• Dyspnea at rest or with minimal exertion AND
• Treatment with at least one dose of IV diuretic or ultrafiltration AND
• At least two of the following signs and symptoms:
• i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest X-ray iv. Local BNP or NT pro-BNP level:
• No current AFib: BNP≥100 pg/mL or NT pro-BNP≥300 pg/mL OR
• Current AFib: BNP≥150 pg/mL or NT pro-BNP≥450 pg/mL 4. Sleep disordered breathing (SDB) documented by screening polygraphy with an AHI≥15 events/hour (e/hr) 5. Patient is able to fully understand study information and sign informed consent

You may not qualify if…

• Right-sided heart failure without left-sided failure
• Current chronic use (within 4 weeks of registry entry) of any PAP therapy (e.g., CPAP, APAP, or bi-level) or contraindicated for PAP therapy
• Sustained systolic blood pressure <80 mmHg at baseline
• Complex congenital heart disease
• Constrictive pericarditis
• Chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day or night)
• Transient ischemic attack (TIA) or Stroke within 3 months prior to registry entry
• Definite clinically evident acute myocardial infarction within 3 months of registry entry
• Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas
• Moderate or greater valvular heart disease as the primary reason for heart failure
• In the opinion of the investigator, the index acute decompensated HF event was not due primarily to uncontrolled AFib with fast ventricular response rate
• Inability to comply with planned study procedures

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• INOVA (Inova Heart and Vascular Institute, Inova Fairfax Hospital) — Falls Church, Virginia, United States
• Herz- und Diabeteszentrum, Nordrhein-Westfalen — Bad Oeynhausen, Ruhr-Universität Bochum, Germany
• Ludgerus Clinic, Department of Cardiology, Clemens Hospital — Münster, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.